Treace Medical Concepts

Lapiplasty corrects the unstable joint at the root of the bunion in three dimensions, whereas traditional osteotomies typically address only the cosmetic bump in two planes. The firm's clinical literature reports a 97% to 99% maintenance of correction at 24 months, compared to recurrence rates as high as 70% for traditional procedures noted in peer-reviewed studies. The procedure uses titanium plating technology patented by Treace to secure the tarsometatarsal joint after repositioning.

Treace Medical Concepts is a publicly traded medical-device company (Nasdaq: TMCI), not a family office or investment vehicle. It is included here because its name appeared in an entity screening context. The company designs, manufactures, and markets surgical systems directly to orthopedic surgeons, with all revenue derived from product sales.

Treace sells its implants and instrumentation directly to hospitals, ambulatory surgery centers, and individual surgeons through a team of direct sales representatives in the United States. The company does not license its technology or operate through distributors. In 2023, it reported revenue of roughly $190 million, up from $143 million in 2022, driven by higher surgical volumes and an expanding active surgeon base.

Treace competes with the foot-and-ankle divisions of large orthopedic companies including Stryker, Arthrex, and Zimmer Biomet, as well as smaller focused players like Paragon 28 and CrossRoads Extremity Systems. The company differentiates by dedicating its entire R&D and sales effort to midfoot and forefoot surgery rather than offering a broad extremity portfolio.

The Lapiplasty system received FDA 510(k) clearance in 2014 and its most recent clearance for expanded indications came in 2020. The Adductoplasty system for midfoot correction was cleared in 2022. All products are marketed under FDA Class II designations for bone fixation instrumentation.